RAPT Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

RAPT Therapeutics hat ein Gesamteigenkapital von $95.5M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $108.5M bzw. $13.0M.

Wichtige Informationen

0%

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgradn/a
BargeldUS$97.91m
EigenkapitalUS$95.51m
GesamtverbindlichkeitenUS$12.96m
GesamtvermögenUS$108.47m

Jüngste Berichte zur Finanzlage

Recent updates

Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

Nov 10
Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Jul 24

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

Jun 13
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 20

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

Feb 21
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Sep 12
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

May 10
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Feb 07
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Oct 12
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jan 25
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Oct 15
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study

Jun 14

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jun 08
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

Mar 15
Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

Feb 15
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

Jan 18
RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction

Jan 08

Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like

Dec 21
Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like

The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares

Nov 23
The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares

Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 19
Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: RAPTDie kurzfristigen Aktiva des Unternehmens ($102.6M) übersteigen seine kurzfristigen Passiva ($10.4M).

Langfristige Verbindlichkeiten: RAPTDie kurzfristigen Vermögenswerte des Unternehmens ($102.6M) übersteigen seine langfristigen Verbindlichkeiten ($2.6M).


Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: RAPT ist schuldenfrei.

Schulden abbauen: RAPT hat in den letzten 5 Jahren keine Schulden gemacht.


Bilanz


Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: RAPT hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: RAPT verfügt über eine ausreichende Liquiditätsreserve für 1 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 22% pro Jahr abnimmt.


Entdecken Sie finanziell stabile Unternehmen